Stock Trading History of Karabelas Argeris N
The following table details the trading activities
(stock purchases, stock sales, and stock option exercises)
reported to
the Securities and Exchange Commission (SEC)
by insider
Karabelas Argeris N since year 2005.
The trader's CIK number is
1191229.
At the time of this reporting, Karabelas Argeris N is the Chairman of the Board of
Vanda Pharmaceuticals Inc.
(stock ticker symbol
VNDA).
Note that in the past
KARABELAS ARGERIS N also reported insider trading activities as an insider of the following companies:
Stock purchases, sales, and option exercises reported by Karabelas Argeris N since 2005.
| Trade Date |
Symbol |
Company Name (Issuer) |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2007-02-23 | VNDA | Vanda Pharmaceuticals Inc. | Sale | 384,130 | 26.02 | 9,993,756 |
| 2007-02-22 | VNDA | Vanda Pharmaceuticals Inc. | Sale | 72,600 | 26.82 | 1,947,328 |
| 2007-02-21 | VNDA | Vanda Pharmaceuticals Inc. | Sale | 237,000 | 26.74 | 6,337,380 |
| 2007-02-20 | VNDA | Vanda Pharmaceuticals Inc. | Sale | 200,000 | 27.37 | 5,474,360 |
| 2006-12-12 | VNDA | Vanda Pharmaceuticals Inc. | Sale | 424,150 | 25.18 | 10,680,097 |
| 2006-12-11 | VNDA | Vanda Pharmaceuticals Inc. | Sale | 326,325 | 26.40 | 8,614,980 |
| 2006-11-27 | VNDA | Vanda Pharmaceuticals Inc. | Sale | 300,000 | 14.18 | 4,254,000 |
| 2006-11-22 | VNDA | Vanda Pharmaceuticals Inc. | Sale | 300,000 | 14.12 | 4,236,000 |
| 2006-11-21 | VNDA | Vanda Pharmaceuticals Inc. | Sale | 50,000 | 14.55 | 727,500 |
| 2006-11-17 | VNDA | Vanda Pharmaceuticals Inc. | Sale | 270,000 | 14.25 | 3,847,500 |
| 2006-11-20 | VNDA | Vanda Pharmaceuticals Inc. | Sale | 50,000 | 15.29 | 764,500 |
| 2006-11-10 | HGSI | Human Genome Sciences Inc | Purchase | 12,500 | 12.15 | 151,875 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Karabelas Argeris N
(Chairman of the Board of Vanda Pharmaceuticals Inc. at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.
